EUCTR2010-021719-18-DE进行中（未招募）不适用
Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA) - AMLSG 17-10
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with newly diagnosed acute myeloid leukemia according to WHO classification and aged = 18 years eligible for an intensive induction chemotherapy with high risk for induction failure and for whom currently no molecularly targeted therapy is available:
- •absence of a t(15;17), t(8;21), inv(16)/t(16;16) and the respective fusion transcripts PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11
- •absence of an activating FLT3-mutation (FLT3-ITD or TKD - mutation)
- •absence of an NPM1 exon12 mutation
- •2. Written informed consent
- •3. No previous cytotoxic chemotherapy for the treatment of AML (exception: oral hydroxyurea for up to 5 days during screening/baseline to control hyperleukocytosis)
- •4. Adequate renal and hepatic functions as indicated by the following laboratory values:
- •Serum creatinine 60 mL/min/1.73 m2, respectively
- •Serum bilirubine • Aspartate aminotransferase (AST/SGOT) /alanine aminotransferase (ALT/SGPT) • Alkaline phosphatase (ALP) 5. Capable of understanding the investigational nature, potential risks and benefits of the study
- •6. Women of childbearing potential must have a negative serum pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to start of IMP treatment
- •7. Female patients must meet one of the following criteria:
- •For female patients > = 50 years of age at the day of inclusion: Menopause since at least 1 year
- •Female patients < 50 years of age at the day of inclusion who meet all of the following criteria:
- •menopause since at least 1 year
- •serum FSH levels > 40 MIU/mL
- •serum estrogen levels < 30 pg/mL or negative estrogen test
- •6 weeks after surgical sterilization by bilateral tubal ligation or bilateral ovariectomy with or without hysterectomy
- •Correct use of two reliable contraception methods from the time of screening/baseline and during the study for a minimum of 90 days after the last administration of study medication. This includes every combination of a hormonal contraceptive (such as injection, transdermal patch, implant, cervical ring) or of an intrauterine device (IUD) with a barrier method (diaphragm, cervical cap, Lea contraceptive, femidom or condom) or with a spermicide. In case the patient takes hormone preparations for suppression of menstruation during the period of aplasia, a suitable and effective method of contraception has to be discussed with the investigator and used by the patient
- •General sexual abstinence from the time of screening/baseline, during the study until a minimum of 90 days after the last administration of study medication
- •Having only female sexual partners
- •Monogamous relationship with sterile male partner
- •8. Male patients must meet one of the following criteria:
- •6 weeks after surgical sterilization by vasectomy
- •Correct use of two reliable contraception methods from the time of screening/baseline and during the study for a minimum of 90 days after the last administration of study medication. This includes every combination of a hormonal contraceptive (such as injection, transdermal patch, implant, cervical ring) or of an intrauterine device (IUD) with a barrier method (diaphragm, cervical cap, Lea contraceptive, femidom or condom) or with a spermicide.
- •General sexual abstinence from the time of screening/baseline during the study until a minimum of 90 days after the last administration of study medication
- •Having only
排除标准
- •1. Current concomitant chemotherapy, radiation therapy or immunotherapy not defined in the study protocol
- •2. Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of oral hydroxyurea. The patient must have recovered from all non-hematological acute toxicities from any previous therapy
- •3. Participation in a clinical trial within 30 days before inclusion in this study or concurrent to this study.
- •4. Bleeding disorder independent of AML
- •5. Patients with uncontrolled systemic fungal, bacterial, viral or other infection (defined as persistent disease signs/symptoms without improvement despite appropriate antibiotics or other treatment)
- •6.Patients with clinically relevant heart disease such as:
- •History of acute myocardial infarction within the last 6 months
- •Heart failure NYHA grade III or IV due to myocardial infarction or other causes
- •Acute inflammatory heart disease
- •Unstable atrial fibrillation or other hemodynamically relevant arrythmias
- •7. HIV infection
- •8. Patients who have received cumulative doses of = 360mg/m2 of doxorubicin or its equivalent to other anrthracyclines, e.g. 900mg/m2 of daunorubicin, 450mg of pegylated liposomal doxorubicin hydrochloride, 225mg/m2 idarubicin or 140mg/m2 mitoxantrone
- •9. Pregnant or lactating women
- •10. Any significant concurrent disease, illness, psychiatric disorder or history of serious organ dysfunction that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
- •11. Diagnosis of another malignancy, unless the patient is disease-free for at least 3 years following the completion of curative intent therapy, with the following exceptions:
- •Myelodysplastic syndrome (MDS) in patients with AML after MDS according to the WHO classification
- •Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.
- •12. Known hypersensitivity to any of the IMPs
研究者
相似试验
招募中
1 期
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeAcute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsHigh Risk Myelodysplastic SyndromeRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory High Risk Myelodysplastic SyndromeNCT04047641M.D. Anderson Cancer Center80
招募中
不适用
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AMLAcute Myeloid LeukemiaNCT06232694The First Affiliated Hospital with Nanjing Medical University54
进行中（未招募）
不适用
A Phase II Study of Elacytarabine plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid LeukaemiaAcute Myeloid Leukaemia (AML)EUCTR2008-008518-38-DEClavis Pharma ASA50
已完成
2 期
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaAcute Undifferentiated LeukemiaAcute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous LineageMixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise SpecifiedMixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise SpecifiedRecurrent Mixed Phenotype Acute LeukemiaMixed Phenotype Acute LeukemiaNCT02135874M.D. Anderson Cancer Center16
已完成
2 期
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaNCT01806571Mayo Clinic34